丹纳赫 DHR

Julie Sawyer Montgomery has served as Executive Vice President since July 2024 after serving as Vice President - Group Executive of Danaher's Diagnostics subsidiary from January 2023 to June 2024 and President of Danaher's Beckman Coulter Diagnostics subsidiary from January 2020 to December 2022. On August 3, 2026, Danaher Corporation announced that, effective as of October 1, 2026, the Board of Directors of the Company has appointed Julie Sawyer Montgomery as President and Chief Executive Officer of the Company. Since joining the Company in 2017, Ms. Sawyer Montgomery, age 54, has served in a series of progressively more responsible general management positions (and as a Danaher officer since 2024), including as President of Danaher's Beckman Coulter Diagnostics subsidiary from January 2020 to December 2022, as Vice President - Group Executive of Danaher's Diagnostics subsidiary from January 2023 to June 2024 and as Executive Vice President since July 2024.

Christopher P. Riley has served as Executive Vice President since January 2024 after serving as Vice President - Group Executive of Danaher's Life Sciences subsidiary from July 2022 to December 2023, Vice President-Group Executive of Danaher's Diagnostics subsidiary from January 2020 to July 2022 and President of Danaher's Beckman Coulter Diagnostics subsidiary from August 2017 to January 2020.

Matthew R. McGrew has served as Executive Vice President and Chief Financial Officer since January 2019. On July 21, 2025, Matthew M. McGrew, Executive Vice President and Chief Financial Officer of Danaher Corporation, notified the Company that he plans to relinquish his role as Chief Financial Officer as of February 28, 2026, after which he will continue as an Executive Vice President of the Company.

Jose-Carlos Gutierrez-Ramos has served as Senior Vice President - Chief Science Officer since joining Danaher in December 2020. Prior to joining Danaher, Dr. Gutierrez-Ramos served as Vice President - Drug Discovery for AbbVie, Inc., a biopharmaceutical company, from January 2020 to December 2020; and as President and CEO of Repertoire Immune Medicines, a biotechnology company, from August 2018 until January 2020.

Teri L. List is an Independent Director of Danaher Corporation, having served on the Board since 2011. Ms. List served as Executive Vice President and Chief Financial Officer of Gap Inc., a global clothing retailer, from January 2017 until March 2020. Prior to joining Gap, she served as Executive Vice President and Chief Financial Officer of Dick's Sporting Goods, Inc., a sporting goods retailer, from August 2015 to August 2016, and with Kraft Foods Group, Inc., a food and beverage company, as Advisor from March 2015 to May 2015, as Executive Vice President and Chief Financial Officer from December 2013 to February 2015 and as Senior Vice President of Finance from September 2013 to December 2013. From 1994 to September 2013, Ms. List served in a series of progressively more responsible positions in the accounting and finance organization of The Procter & Gamble Company, a consumer goods company, most recently as Senior Vice President and Treasurer. Prior to joining Procter & Gamble, Ms. List was employed by the accounting firm of Deloitte & Touche for almost ten years. Within the past five years, Ms. List served on the board of directors of Oscar Health, Inc. and DoubleVerify Holdings, Inc.

A. Shane Sanders is an Independent Director of Danaher Corporation, having served on the Board since 2021. Mr. Sanders served in a series of progressively more responsible leadership positions with Verizon Communications Inc., a telecommunications company, from 1997 until December 2022, including most recently as Senior Vice President of Business Transformation from March 2020 to December 2022 and as Senior Vice President of Corporate Finance from 2015 to March 2020. Alongside Verizon's Chief Security Officer, Mr. Sanders led the implementation of the Verizon Enterprise Security Council which focused on cybersecurity and IT security risk management. Prior to joining Verizon, Mr. Sanders served in various finance roles at Hallmark Cards, Inc., a retailer of greeting cards and gifts, and Safelite Group, Inc., a provider of vehicle glass repair, and began his career at Grant Thornton, an audit, tax and advisory firm, in 1984.

Elias A. Zerhouni, MD is an Independent Director of Danaher Corporation, having served on the Board since 2009. Dr. Zerhouni has served as President and Vice Chairman of the Board of OPKO Health, Inc. a medical test and medication company, since May 2022. He was chairman and co-founder of ModeX Therapeutics Inc., a biotechnology company focused on multi specific-immune therapies for cancer and viral diseases, from October 2020 until its acquisition by OPKO in May 2022. Dr. Zerhouni previously served as President, Global Research & Development, for Sanofi S.A., a global pharmaceutical company, from 2011 to June 2018. From 2008 until 2011, Dr. Zerhouni provided advisory and consulting services to various non-profit and other organizations as Chairman and President of Zerhouni Holdings. From 2002 to 2008, he served as director of the National Institutes of Health, and from 1996 to 2002, he served as Chair of the Russell H. Morgan Department of Radiology and Radiological Sciences, Vice Dean for Research and Executive Vice Dean of the Johns Hopkins School of Medicine.

Alan G. Spoon is an Independent Director of Danaher Corporation, having served on the Board since 1999. Mr. Spoon served as Partner Emeritus of Polaris Partners, an investment firm, from January 2016 to June 2018, Managing General Partner from 2000 to 2010 and Partner from 2000 to 2018. Within the past five years, Mr. Spoon served on the board of directors of Cable One, Inc., Match Group, and Fortive Corporation. In addition to his leadership roles at Polaris Partners, Mr. Spoon has previously served as president, chief operating officer and chief financial officer of one of the country's largest, publicly-traded education and media companies, and has served on the boards of numerous public and private companies.

Raymond C. Stevens, PhD is an Independent Director of Danaher Corporation, having served on the Board since 2017. Professor Stevens has served as Chief Executive Officer, and as a director, of Structure Therapeutics (formerly known as ShouTi), a biotechnology company, since May 2019. He also served as Provost Professor of Biological Sciences and Chemistry, and Founder and Director of The Bridge Institute, at the University of Southern California, a private research university, from July 2014 to August 2021. From 1999 until July 2014, he served as Professor of Molecular Biology and Chemistry with The Scripps Research Institute, a non-profit research organization. Professor Stevens has also launched multiple biotechnology companies focused on drug discovery.

Steven M. Rales is the Chairman of the Board of Danaher Corporation, having served on the Board since 1983. Mr. Rales is a co-founder of Danaher and has served as Danaher's Chairman of the Board since 1984. He was also CEO of the Company from 1984 to 1990. Mr. Rales is a brother of Mitchell P. Rales. Within the past five years, Mr. Rales served on the board of directors of Fortive Corporation.

Mitchell P. Rales is a Director of Danaher Corporation, having served on the Board since 1983. Mr. Rales is a co-founder of Danaher and has served as Chairman of the Executive Committee of Danaher since 1984. He was also President of the Company from 1984 to 1990. Mr. Rales is a brother of Steven M. Rales. Within the past five years, Mr. Rales served on the board of directors of Fortive Corporation and Enovis Corporation.

R. Bradley Gray has served as Senior Vice President - Strategic Development since joining Danaher in September 2024. Prior to joining Danaher, Mr. Gray served as President and CEO, and as a member of the board of directors, of NanoString Technologies, Inc., a biotechnology company, from 2010 to May 2024. NanoString filed for bankruptcy in February 2024.

Jonathan Leiken has served as Senior Vice President - Chief Legal Officer since joining Danaher in August 2025. Prior to joining Danaher, Mr. Leiken served as Executive Vice President - Chief Legal Officer and Corporate Secretary of Dollar Tree Inc., a discount retailer, from August 2023 to August 2025, and as Executive Vice President - Chief Legal Officer and Secretary of Diebold Nixdorf, Inc., a financial and retail technology company, from 2014 to August 2023. Diebold Nixdorf and certain of its affiliated Dutch entities successfully completed voluntary, pre-packaged debt restructuring proceedings under US and Dutch bankruptcy law between June 2023 (filing) and August 2023 (emergence).

Christopher M. Bouda will succeed Mr. Lutz as Vice President-Chief Accounting Officer as of January 1, 2022. Mr. Bouda has served as Danaher's Vice President-Finance since joining Danaher in August 2016.

Greg M. Milosevich has served as Executive Vice President since July 2025 after serving as Vice President - Group Executive of Danaher's Life Science Innovations subsidiary from November 2021 through June 2025 and as President of Danaher's Beckman Coulter Life Sciences subsidiary from June 2019 through October 2021.

Effective February 28, 2026, Matthew E. Gugino will be appointed as Executive Vice President-Chief Financial Officer. Mr. Gugino, 43, currently serves as Danaher's Vice President-Corporate FP&A and Group CFO with responsibility for the Life Sciences Innovations businesses. Since joining Danaher in 2013, Mr. Gugino has served in a series of progressively more responsible positions in the Company's finance and investor relations organizations, including as Vice President-Investor Relations from 2014 to March 2022. He assumed the FP&A portion of his current role in July 2019 and the Group CFO portion of his current role in April 2021.